Hyloris Pharmaceuticals (XBRU:HYL) EV-to-Revenue : 106.13 (As of May. 02, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Hyloris Pharmaceuticals's enterprise value is €298.66 Mil. Hyloris Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €2.81 Mil. Therefore, Hyloris Pharmaceuticals's EV-to-Revenue for today is 106.13.

The historical rank and industry rank for Hyloris Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

XBRU:HYL' s EV-to-Revenue Range Over the Past 10 Years
Min: 80.52 Med: 116.81 Max: 2932.76
Current: 106.13

During the past 8 years, the highest EV-to-Revenue of Hyloris Pharmaceuticals was 2932.76. The lowest was 80.52. And the median was 116.81.

XBRU:HYL's EV-to-Revenue is ranked worse than
84.62% of 1034 companies
in the Biotechnology industry
Industry Median: 7.82 vs XBRU:HYL: 106.13

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-02), Hyloris Pharmaceuticals's stock price is €11.70. Hyloris Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.10. Therefore, Hyloris Pharmaceuticals's PS Ratio for today is 117.00.

Hyloris Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Hyloris Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals EV-to-Revenue Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

1,082.57

140.19

95.48

116.58

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial							140.19	-	95.48	-	116.58

Competitive Comparison of Hyloris Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Hyloris Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's EV-to-Revenue falls into.

Hyloris Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Hyloris Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	298.660	/	2.814
	=	106.13

Hyloris Pharmaceuticals's current Enterprise Value is €298.66 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hyloris Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €2.81 Mil.

Hyloris Pharmaceuticals (XBRU:HYL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Hyloris Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	11.70	/	0.1
	=	117.00

Hyloris Pharmaceuticals's share price for today is €11.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was €0.10.

Hyloris Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

52U:Germany

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.